Strategies to manage low-bone turnover;Strategies to manage low-bone turnover

Nefrologia

Volumn 29, Issue 4, 2009, Pages 295-297

  Spasovski, G ^a  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

Author keywords

Adynamic bone disease; Calcium based phosphate binders; Low calcium dialysate; Non calcium based phosphate binders

Indexed keywords

CHELATING AGENT; POLYAMINE; SEVELAMER;

BONE; BONE DISEASE; HUMAN; METABOLISM; REVIEW;

BONE AND BONES; BONE DISEASES; CHELATING AGENTS; HUMANS; POLYAMINES;

EID: 70449711494     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/NEFROLOGIA.2009.29.4.5399.EN.FULL     Document Type: Review

References (17)

1. Spasovski G. Bone biopsy as a diagnostic tool in the assessment of renal osteodrophy. Int J Artif Organs 2004; 27(11):918-23
2. Spasovski G, Bervoets A, Behets G, et al. Spectrum of renal bone disease in end-stage renal failure patients not in dialysis yet. Nephrol Dial Transplant 2003; 18:1159-1166.
3. Brandenburg VM & Floege J. Adynamic bone disease-bone and beyond. NDT plus 2008; 3: 135-147.
4. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? Nephrol Dial Transpl 2004; 19 Suppl 1: i9-13.
5. Spasovski G. Low turn-over bone disease in patients with chronic renal disease. Med Pregl 2007; 60 Suppl 2:21-4.
6. Goodman WG, Goldin SJ, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-83, 2000.
7. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on allcause and cardiovascular mortality. Nephrol Dial Transplant 18(9): 1731-40, 2003
8. Spasovski G. New aspects of treatment of renal bone disease in dialysis patients. Prilozi 2007; 28(1):205-13.
9. Spasovski G. Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol 2007;39(4):1209-16.
10. Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in haemodialysis. J Bone Miner Res. 2005;20(5):764-72.
11. Ferreira A, Frazao J et al. Effects of Sevelamer Hydrochloride and Calcium Carbonate on ROD in HD Patients. J Am Soc Nephrol 2008; 19: 405-12.
12. Iwata Y et al. Effect of Sevelamer on Markers of Bone Turnover in Japanese HD Patients with Low iPTH Levels. Intern Med 2007; 46(8):447-52.
13. D'Haese PC, Spasovski GB et al. A multicenter study on the effect of lanthanum carbonate and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63: Suppl 85:73-78.
14. Spasovski G, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1-year treatment with lanthanum carbonate and after two years of follow up. Nephrol Dial Transplant 2006; 21(8):2217-24.
15. Malluche H et al. Effects of Treatment of Renal Osteodystrophy on Bone Histology. Clin J Am Soc Nephrol 2008; 3: S157-S163.
16. Haris A et al. Lowered Dialysate Calcium in PD: Increased PTH and Bone Formation. Kidney Int 2006; 70(5):931-7.
17. Spasovski G et al. Improvement of Bone and Mineral Parameters Related to Adynamic Bone Disease by Diminishing Dialysate Calcium. Bone 2007; 41: 698-703.